Home › Kidney Cancer (Renal Cell Carcinoma) › NCT07092566

R.E.C.K vs Exparel in Robotic Nephrectomy

Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Ability to understand and willingness to sign an IRB-approved informed consent
2. Age ≥ 18 years at the time of consent.
3. Planned robotic partial or radical nephrectomy

Exclusion Criteria:

1. Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator
2. Known pregnancy
3. Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME/day)
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
5. Known allergy to R.E.C.K. and/or Exparel

About the study

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

What is being tested

• Ropivacaine HCL (drug)
• Exparel (drug)
• Epinephrine (drug)
• Clonidine HCL (drug)
• Ketorolac (drug)

Sponsor: Wake Forest University Health Sciences · Participants: 170 · Started: Nov 14, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07092566

Locations in the U.S.

Conditions

• Kidney Cancer (Renal Cell Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.